Drug Trial Radar · NCT01296191
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
Last checked: Nov 20, 2026Latest source record: Dec 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
May 2011
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- Frank A. Bucci, Jr., M.D.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
Conditions
- Cataracts
Interventions
MoxifloxacinDrug
One drop 4 times daily for 3 days and one drop the day of sample collection
besifloxacinDrug
One drop 4 times daily for 3 days and one drop on day of sample collection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics in Aqueous Humor Samples.Time frame: Measured after 3 days of drug instillation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bucci Laser Vision Institute
Wilkes-Barre, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.